Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TUXARIN ER vs ABSTRAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
TUXARIN ER contains dextromethorphan, an NMDA receptor antagonist and sigma-1 receptor agonist, and bupropion, a norepinephrine and dopamine reuptake inhibitor. The combination is thought to modulate glutamatergic neurotransmission and enhance dopaminergic and noradrenergic signaling.
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Major depressive disorder (FDA-approved as Auvelity),Treatment-resistant depression (off-label)
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
1 tablet orally every 12 hours; each tablet contains chlorpheniramine maleate 8 mg and phenylephrine HCl 20 mg.
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
The terminal elimination half-life (t1/2) of chlorpheniramine is approximately 14–25 h in adults, allowing twice-daily dosing. Pseudoephedrine has a shorter t1/2 of 5–8 h in normal renal function, but the ER formulation maintains therapeutic levels for 12 h. In renal impairment, pseudoephedrine half-life prolongs significantly, requiring dose adjustment.
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Bupropion is extensively metabolized via CYP2B6 to hydroxybupropion, while dextromethorphan is metabolized primarily by CYP2D6 to dextrorphan. Both are further metabolized by other enzymes.
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
TUXARIN ER is a combination antihistamine/decongestant. The antihistamine component (e.g., chlorpheniramine) is extensively metabolized via CYP450; its metabolites and parent drug (∼68% over 48 h) appear in urine as unchanged drug and metabolites. The decongestant (e.g., pseudoephedrine) is primarily excreted unchanged in urine (∼70–90%) with the remainder metabolized in liver; renal elimination is p H-dependent, with acidic urine increasing excretion. Fecal elimination is negligible (<5%).
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
Chlorpheniramine: ∼70% bound to plasma proteins (mainly albumin). Pseudoephedrine: negligible protein binding (<20%).
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
Chlorpheniramine: Vd ≈ 3–5 L/kg, indicating extensive tissue distribution. Pseudoephedrine: Vd ≈ 2.5–3.5 L/kg, consistent with distribution into total body water. Larger Vd suggests sequestration in tissues like lungs and spleen.
4-6 L/kg; large Vd indicates extensive tissue distribution
Chlorpheniramine: Oral bioavailability ∼25–50% due to first-pass metabolism. Pseudoephedrine: Oral bioavailability ∼100% (>90% absorbed, low first-pass effect). The ER formulation maintains equivalent bioavailability with reduced peak concentrations.
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
Contraindicated in severe renal impairment (Cr Cl <30 m L/min). No specific dose adjustment for mild to moderate impairment; use with caution.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
Contraindicated in severe hepatic impairment (Child-Pugh class C). Use with caution in moderate impairment (Child-Pugh class B); no specific dose adjustment defined.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
Not recommended for children under 12 years. For children 12 years and older, same as adult dosing: 1 tablet every 12 hours.
Not approved for pediatric patients <18 years; safety and efficacy not established.
Use with caution due to increased sensitivity to anticholinergic effects (e.g., confusion, urinary retention). Lower initial dose may be considered; avoid use in patients with prostate hypertrophy or glaucoma.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
WARNING: SUICIDALITY AND ANTIDEPRESSANT DRUGS - Antidepressants increased the risk of suicidal thinking and behavior in children, adolescents, and young adults in short-term studies. Monitor closely for clinical worsening and emergence of suicidal thoughts and behaviors.
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Increased risk of suicidal thoughts and behaviors; activation of mania/hypomania; seizures (dose-dependent); increased blood pressure; angle-closure glaucoma; serotonin syndrome; hepatotoxicity; neuropsychiatric reactions; allergic and anaphylactic reactions.
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Concurrent use with MAOIs; seizure disorder; history of anorexia nervosa or bulimia; abrupt discontinuation of alcohol, benzodiazepines, or anticonvulsants; known hypersensitivity to any component; use of other bupropion-containing products; concomitant use with linezolid or methylene blue.
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
Avoid alcohol and grapefruit juice. Grapefruit juice may inhibit CYP3A4 metabolism of triprolidine, increasing its levels. High-tyramine foods (e.g., aged cheeses, cured meats) may interact with pseudoephedrine, increasing pressor effects. Take with or without food; food may reduce GI irritation but does not affect absorption.
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
TUXARIN ER contains chlorpheniramine and pseudoephedrine. Chlorpheniramine is an antihistamine classified as FDA Pregnancy Category B; animal studies show no risk but no adequate human studies. Pseudoephedrine is FDA Pregnancy Category C; in first trimester, case-control studies suggest a possible association with gastroschisis (odds ratio ~1.8-2.2). After 32 weeks, use may cause premature uterine contractions or fetal tachycardia. Avoid in third trimester due to risk of neonatal irritability and respiratory depression.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
Chlorpheniramine is excreted into breast milk in small amounts (M/P ratio not established). Pseudoephedrine is excreted into breast milk; M/P ratio approximately 3. Initial data indicate pseudoephedrine may reduce milk production by up to 24% with single doses. Use with caution; avoid in cases of established lactation insufficiency. American Academy of Pediatrics considers both drugs compatible with breastfeeding but may cause irritability in infants.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
No formal dose adjustments established for pregnancy. However, increased plasma volume and renal clearance in pregnancy may reduce pseudoephedrine levels; monitor clinical response. Avoid extended-release formulations if rapid BP fluctuations are a concern. Consider using the lowest effective dose for shortest duration.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
TUXARIN ER is a fixed-dose combination of pseudoephedrine (120 mg) and triprolidine (2.5 mg) in an extended-release formulation. The delayed-release component may reduce dosing frequency to every 12 hours. Monitor for CNS stimulation; avoid in severe hypertension or coronary artery disease. Use caution in elderly due to anticholinergic effects (triprolidine).
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
Do not crush or chew the tablet; swallow whole with a full glass of water.,Take every 12 hours; do not exceed 2 tablets in 24 hours.,Avoid driving or operating heavy machinery until you know how this medication affects you.,Notify your doctor if you have high blood pressure, heart disease, glaucoma, or urinary retention.,Do not use with other products containing antihistamines or decongestants.,Stop use and seek medical attention if you experience chest pain, rapid heartbeat, or severe dizziness.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TUXARIN ER vs ABSTRAL, answered by our medical review team.
TUXARIN ER is a Antitussive/decongestant combination that works by TUXARIN ER contains dextromethorphan, an NMDA receptor antagonist and sigma-1 receptor agonist, and bupropion, a norepinephrine and dopamine reuptake inhibitor. The combination is thought to modulate glutamatergic neurotransmission and enhance dopaminergic and noradrenergic signaling.. ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TUXARIN ER and ABSTRAL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TUXARIN ER is: 1 tablet orally every 12 hours; each tablet contains chlorpheniramine maleate 8 mg and phenylephrine HCl 20 mg.. The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TUXARIN ER and ABSTRAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TUXARIN ER is classified as Category C. TUXARIN ER contains chlorpheniramine and pseudoephedrine. Chlorpheniramine is an antihistamine classified as FDA Pregnancy Category B; animal studies show no risk but no adequate h. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.